Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001

European Journal of Cancer

Volumn 47, Issue 8, 2011, Pages 1244-1257

  Kuo, Sung Hsin ^a,b   Hsu, Chih Hung ^a,b   Chen, Li Tzong ^c,d   Lu, Yen Sen ^a,b   Lin, Ching Huang ^a,b   Yeh, Pei Yen ^a,b   Jeng, Huei Jiuan ^a,b   Gao, Ming ^a,b   Yeh, Kun Huei ^a,b   Cheng, Ann Lii ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AKT; c Myc; Cyclin D3; eIF4E; IRS 1; mTOR; RAD001

Indexed keywords

CYCLIN A; CYCLIN D3; CYCLIN E; EVEROLIMUS; INITIATION FACTOR 4E; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P27;

ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; LIVER CELL CARCINOMA; LYMPHOMA; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CARCINOMA;

APOPTOSIS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; LYMPHOMA; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TETRAZOLIUM SALTS; THIAZOLES; TOR SERINE-THREONINE KINASES;

EID: 79955525981     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.01.003     Document Type: Article

References (45)

1. B.T. Hennessy, E.O. Hanrahan, and P.A. Daly Non-Hodgkin lymphoma: an update Lancet Oncol 5 2004 341 353 (Pubitemid 38691037)
2. T.P. Miller, C.M. Spier, and L. Rimsza Diffuse aggressive histologies of non-hodgkin lymphoma: treatment and biology of limited disease Semin Hematol 43 2006 207 212 (Pubitemid 44486314)
3. M. Rudelius, S. Pittaluga, and S. Nishizuka Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma Blood 108 2006 1668 1676 (Pubitemid 44316136)
4. S. Uddin, A.R. Hussain, and A.K. Siraj Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood 108 2006 4178 4186 (Pubitemid 44913290)
5. F. Vega, L.J. Medeiros, and V. Leventaki Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma Cancer Res 66 2006 6589 6597 (Pubitemid 44085614)
6. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Gene Dev 18 2004 1926 1945 (Pubitemid 39071573)
7. C. Tokunaga, K. Yoshino, and K. Yonezawa MTOR integrates amino acid- and energy-sensing pathways Biochem Biophys Res Commun 313 2004 443 446 (Pubitemid 37543606)
8. S. Wang, I.B. Rosenwald, and M.J. Hutzler Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas Am J Pathol 155 1999 247 255 (Pubitemid 29318722)
9. D.C. Fingar, and J. Blenis Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Oncogene 23 2004 3151 3171 (Pubitemid 38638827)
10. D. Ruggero, L. Montanaro, and L. Ma The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis Nat Med 10 2004 484 486 (Pubitemid 38667906)
11. H.G. Wendel, E. De Stanchina, and J.S. Fridman Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 428 2004 332 337 (Pubitemid 38418805)
12. M.E. Bordeleau, F. Robert, and B. Gerard Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model J Clin Invest 118 2008 2651 2660 (Pubitemid 351949792)
13. V.I. Brown, J. Fang, and K. Alcorn Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling Proc Natl Acad Sci USA 100 2003 15113 15118 (Pubitemid 37518025)
14. T.E. Witzig, S.M. Geyer, and I. Ghobrial Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma J Clin Oncol 23 2005 5347 5356 (Pubitemid 46206988)
15. K. Wanner, S. Hipp, and M. Oelsner Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab Br J Haematol 134 2006 475 484 (Pubitemid 44141713)
16. Y. Mamane, E. Petroulakis, O. LeBacquer, and N. Sonenberg MTOR, translation initiation and cancer Oncogene 25 2006 6416 6422 (Pubitemid 44582285)
17. T. Haritunians, A. Mori, and J. O'Kelly Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma Leukemia 21 2007 333 339 (Pubitemid 46158128)
18. Kuo SH, Hsu CH, Yeh PY, et al. RAD001 (everolimus) down-regulates cyclin D3 and c-Myc and is particularly effective in the treatment of aggressive B-cell lymphomas. J Clin Oncol 2006;24(18 suppl):Abstract 17573.
19. C.H. Hsu, M. Gao, C.L. Chen, P.Y. Yeh, and A.L. Cheng Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro Oncology 68 2005 538 547 (Pubitemid 41160987)
20. S.H. Kuo, P.Y. Yeh, and L.T. Chen Overexpression of B-cell activating factor of TNF Family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma Blood 112 2008 2927 2934
21. K.E. O'Reilly, F. Rojo, and Q.B. She MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508 (Pubitemid 43259931)
22. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L.J. Helman Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 2007 1932 1940 (Pubitemid 46474636)
23. R.T. Woodland, C.J. Fox, and M.R. Schmidt Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival Blood 111 2008 750 760
24. P.S. Hammerman, C.J. Fox, M.J. Birnbaum, and C.B. Thompson Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival Blood 11 2005 4477 4483 (Pubitemid 40720797)
25. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501 (Pubitemid 37328931)
26. F. McCormick Cancer: survival pathways meet their end Nature 428 2004 267 269 (Pubitemid 38418785)
27. R.L. Silva, and H.G. Wendel MNK, EIF4E and targeting translation for therapy Cell Cycle 7 2008 553 555 (Pubitemid 351498989)
28. S.Y. Sun, L.M. Rosenberg, and X. Wang Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition Cancer Res 65 2005 7052 7058 (Pubitemid 41161231)
29. X. Wang, P. Yue, and C.B. Chan Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation Mol Cell Biol 27 2007 7405 7413 (Pubitemid 350033648)
30. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101 (Pubitemid 40262113)
31. H. Nojima, C. Tokunaga, and S. Eguchi The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif J Biol Chem 278 2003 15461 15464 (Pubitemid 36799651)
32. G.G. Chiang, and R.T. Abraham Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase J Biol Chem 280 2005 25485 25490 (Pubitemid 40962253)
33. K.W. Yee, Z. Zeng, and M. Konopleva Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 2006 5165 5173 (Pubitemid 44453345)
34. M. Hidalgo, J.C. Buckner, and C. Erlichman A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer Clin Cancer Res 12 2006 5755 5763 (Pubitemid 44629606)
35. Y. Shi, H. Yan, P. Frost, J. Gera, and A. Lichtenstein Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade Mol Cancer Ther 4 2005 1533 1540 (Pubitemid 41556435)
36. J. Tamburini, N. Chapuis, and V. Bardet Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/AKT by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia; rationale for therapeutic inhibition of both pathways Blood 111 2008 379 382
37. H.G. Wendel, A. Malina, and Z. Zhao Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo Cancer Res 66 2006 7639 7646 (Pubitemid 44289221)
38. H.G. Wendel, R.L. Silva, and A. Malina Dissecting eIF4E action in tumorigenesis Genes Dev 21 2007 3232 3237 (Pubitemid 350277750)
39. C.O. Nathan, L. Liu, and B.D. Li Detection of the protooncogene eIF4E in surgical margins may predict recurrence in head and neck cancer Oncogene 15 1997 579 584 (Pubitemid 27384735)
40. B.D. Li, J.C. McDonald, R. Nassar, and A. De Benedetti Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression Ann Surg 227 1998 756 761
41. M.A. Bjornsti, and P.J. Houghton The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 2004 335 348 (Pubitemid 38579480)
42. C.J. Lin, R. Cencic, J.R. Mills, F. Robert, and J. Pelletier C-Myc and eIF4F are components of a feedforward loop that links transcription and translation Cancer Res 68 2008 5326 5334
43. S. Hipp, I. Ringshausen, and M. Oelsner Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells Haematologica 90 2005 1433 1444
44. D.D. Sarbassov, S.M. Ali, and S. Sengupta Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 22 2006 159 168
45. D.A. Guertin, and D.M. Sabatini An expanding role for mTOR in cancer Trends Mol Med 11 2005 353 361 (Pubitemid 41080576)